Evidence map›Paper›PMID 31515433›Full record

ArticleBMJ open2019

Organisational and financial consequences of the early discharge of patients treated for acute bacterial skin and skin structure infection and osteomyelitis in infectious disease departments in Greece, Italy and Spain: a scenario analysis.

Umberto Restelli, Marzia Bonfanti, Davide Croce, Santiago Grau, Symeon Metallidis, Santiago Moreno Guillén, Valeria Pacelli, Giuliano Rizzardini, Marco Soro, Athanasios Vozikis and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMJ open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Home infusion services in Saudi Arabia: Where are we standing?Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 5 countries.

Umberto RestelliCenter for Health Economics, Social and Health Care Management, LIUC-Università Cattaneo, Castellanza, Italy urestelli@gmail.com.
Marzia BonfantiCenter for Health Economics, Social and Health Care Management, LIUC-Università Cattaneo, Castellanza, Italy.
Davide CroceCenter for Health Economics, Social and Health Care Management, LIUC-Università Cattaneo, Castellanza, Italy.
Santiago GrauPharmacy Department, Hospital del Mar, Barcelona, Spain.
Symeon MetallidisMedical School of Aristotle University of Thessaloniki, Thessaloniki, Greece.
Santiago Moreno GuillénDepartment of Infectious Diseases, Hospital Ramón y Cajal, University of Alcalá, Madrid, Spain.
Valeria PacelliCenter for Health Economics, Social and Health Care Management, LIUC-Università Cattaneo, Castellanza, Italy.
Giuliano RizzardiniDepartment of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital, Milan, Italy.
Marco SoroGlobal HEOR, Angelini, Roma, Lazio, Italy.
Athanasios VozikisLaboratory of Health Economics and Management, University of Piraeus, Piraeus, Greece.
Alastair GrayHealth Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK.ORCID 0000-0003-0239-7278
University Carlo Cattaneo · ITUniversity of the Witwatersrand · ZAAristotle University of Thessaloniki · GRHospital Del Mar · ESUniversidad de Alcalá · ESUniversity of Oxford · GBUniversity of Piraeus · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of the analysis is to assess the organisational and economic consequences of adopting an early discharge strategy for the treatment of acute bacterial skin and skin structure infection (ABSSSI) and osteomyelitis within infectious disease departments.

settingInfectious disease departments in Greece, Italy and Spain.

participantsNo patients were involved in the analysis performed.

interventionsAn analytic framework was developed to consider two alternative scenarios: standard hospitalisation care or an early discharge strategy for patients hospitalised due to ABSSSI and osteomyelitis, from the perspective of the National Health Services of Greece, Italy and Spain. The variables considered were: the number of annual hospitalisations eligible for early discharge, the antibiotic treatments considered (ie, oral antibiotics and intravenous long-acting antibiotics), diagnosis-related group (DRG) reimbursements, number of days of hospitalisation, incidence and costs of hospital-acquired infections, additional follow-up visits and intravenous administrations. Data were based on published literature and expert opinions. PRIMARY AND SECONDARY OUTCOME MEASURES: Number of days of hospitalisation avoided and direct medical costs avoided.

resultsThe total number of days of hospitalisation avoided on a yearly basis would be between 2216 and 5595 in Greece (-8/-21 hospital beds), between 15 848 and 38 444 in Italy (-57/-135 hospital beds) and between 7529 and 23 520 in Spain (-27/-85 hospital beds). From an economic perspective, the impact of the early discharge scenario is a reduction between €45 036 and €149 552 in Greece, a reduction between €182 132 and €437 990 in Italy and a reduction between €292 284 and €884 035 in Spain.

conclusionsThe early discharge strategy presented would have a positive organisational impact on National Health Services, leading to potential savings in beds, and to a reduction of hospital-acquired infections and costs.

Indexed as

Anti-Bacterial AgentsCritical PathwaysHospitalizationOsteomyelitisSkin Diseases, BacterialCost SavingsCross InfectionGreeceHospital DepartmentsHumansIncidenceItalyOutliers, DRGPatient DischargeSpainStatistics as TopicAnti-Bacterial AgentsEconomic evaluationHospital acquired infectionHospital bedsInfectious DiseasesOrganisation

Identifiers

PMID31515433
PMCPMC6747647
OpenAlexW2972789093

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.